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An organometallic structure-activity relationship
study reveals the essential role of a Re(CO)3 moiety
in the activity against gram-positive pathogens
including MRSA†
Malay Patra,a Michaela Wenzel,c Pascal Prochnow,c Vanessa Pierroz,b Gilles Gasser,b
Julia E. Bandow*c and Nils Metzler-Nolte*a
The worrying appearance of microbial resistance to antibiotics is a worldwide problem which needs to be
tackled urgently. Microbial resistance to the common classes of antibiotics involving purely organic
compounds unfortunately develops very rapidly and in most cases, resistance was detected soon after or
even before release of the antibiotic to the market. Therefore, novel concepts for antibiotics must be
investigated, and metal-containing compounds hold particular promise in that area. Taking a trimetallic
complex (1a) which contains a ferrocenyl (Fc), a CpMn(CO)3 (cymantrene) and a [(dpa)Re(CO)3] residue
as the lead structure, a systematic structure–activity relationship (SAR) study against various gram-
positive pathogenic bacteria including methicillin-resistant Staphylococcus aureus (MRSA) strains was
performed. The [(dpa)Re(CO)3] moiety was discovered to be the essential unit for the observed
antibacterial activity of 1a. The ferrocenyl and CpMn(CO)3 units can be replaced one by one or both
together by organic moieties such as a phenyl ring without loss of antibacterial activity. The most potent
mono-metallic complex (9c0) has an antibacterial activity comparable to the well-established organic
drugs amoxicillin and norﬂoxacin and importantly, only moderate cytotoxicity against mammalian cells.
Microbiological studies on membrane potential, membrane permeabilization, and cell wall integrity
revealed that 9c0 targets the bacterial membrane and disturbs cell wall integrity, but shows more eﬃcient
membrane permeabilization than the lead structure 1a.
Introduction
The steady increase of microbial resistance to commercial
drugs is a serious health issue worldwide. One pathogen of
high clinical importance is methicillin-resistant Staphylo-
coccus aureus (MRSA), which oen is not only resistant to
methicillin but also to other clinically used antibiotics such as
gentamycin, erythromycin, and neomycin.1,2 The treatment of
bacterial infections with such multi-resistant germs is there-
fore highly diﬃcult. Even in developed countries like the US,
over 100 000 life-threatening MRSA infections were reported in
2005.3 According to a report by the European Centre of Disease
Control and Prevention, MRSA has reached an average preva-
lence of 50% in Europe.4 Microbial resistance to conventional
organic antibiotics oen develops and spreads amazingly
fast.1 In the case of several antibiotics like linezolid or some b-
lactams, resistance was observed already before the compound
was commercialized for human use.5–7 In parallel with the rst
occurrence of noticeable antimicrobial resistance in the 1990s,
the annual approval rate of antibiotic therapeutics decreased
steadily. Currently, on average, only one antibiotic per year
reaches the market.1,8 The most recent data on compounds in
clinical trials in stages I–III have been compiled in an excellent
review article.9 Although the concurrence of growing antimi-
crobial resistance and the decline of newly approved antibi-
otics may be accidental, in eﬀect the number of new
antibiotics that have been discovered or commercialized in the
last two decades is insuﬃcient to control infections with
multi-resistant pathogens. These facts clearly emphasize the
need for new classes of antimicrobial compounds. The best
candidates for resistance-breaking antibacterials are
compounds which either possess completely new modes of
action, target more than one bacterial structure, or attack
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essential structures that are less prone to target mutation such
as the bacterial cell envelope.10
It was earlier shown that derivatization with organometallic
fragments is able to overcome the resistance problem of
conventional organic drug candidates.11 The rationale behind
this idea is that the metal-based compounds might oﬀer metal-
specic modes of action not available for organic drugs.12,13 This
strategy was shown to be very successful for the antimalarial
drug candidate chloroquine (CQ). Ferroquine (FQ, Fig. 1) is a
ferrocene derivative of CQ. FQ is not only capable of overcoming
the resistance problem of CQ but also showed enhanced anti-
malarial activity compared to CQ.14 Mechanistic investigation
suggested that the activity of FQ against the CQ-resistant
P. falciparum is related to increased lipophilicity, change in
basicity, and introduction of redox-properties into the molecule
by the ferrocene moiety.15,16
Despite promising results in anticancer and antimalarial
research,11,13,14,18 recent research into organometallic
compounds with antibacterial activity is quite limited,19
although their potential for treatment of infectious diseases was
already proven in the early 1900s by the discovery of salvarsan
(Fig. 1), an organoarsenical antimicrobial agent.20,21 Impor-
tantly, at that time, salvarsan was the only treatment option
available for the deadly bacterial infection Syphilis. As an
exception, silver complexes with N-heterocyclic carbene (NHC)
ligands are emerging as a class of promising compounds.22,23
For example Silvamist (Fig. 1), a caﬀeine derived Ag–NHC
complex, exhibits high activity against tobramycin-resistant
pathogenic bacteria in vitro as well as in vivo.22,24
Since a few years, our groups are involved in the develop-
ment of organometallic-containing antibacterial agents.19,25–32
Very recently, we discovered the potent antibacterial activity of
the hetero-tri-organometallic compound 1a (see Table 1 for
structure).33 Being a structurally new class of antibacterial
agents, 1a inhibits the growth of gram-positive bacteria,
includingMRSA, at a minimal inhibitory concentration (MIC) of
2 mg mL1 (1.4 mM, Table 1). The activity of 1a against MRSA is
90 times higher than that of the commercial antibacterial agent
amoxicillin (MIC 1/4 48 mg mL1, 131 mM), and comparable to
that of noroxacin (MIC 1/4 0.5 mg mL1, 1.6 mM). A ruth-
enocene derivative, 1b (see Table 1 for its structure), was found
to be slightly less active than 1a. A mechanism-of-action study
revealed that both compounds interact strongly with the
bacterial membrane and interfere with membrane-associated
processes such as cell wall biosynthesis and respiration.33
Additionally, 1a induces oxidative stress in bacteria, which is
not the case for 1b. The solubility of both compounds was
around 25 mg mL1 in aqueous solution, thereby limiting
pharmacological evaluation of the compounds. However, due to
its impressive antibacterial activity, we decided to rationalize
the activity of 1a. In addition, we aimed at obtaining easy-to-
synthesize derivatives with higher solubility while retaining or
improving antibacterial potency and selectivity over mamma-
lian cells. Also, we considered it crucial to understand the
importance of each organometallic moiety present in 1a,
namely ferrocene, CpMn(CO)3, and [(dpa)Re(CO)3], and to
dene their individual contribution to antibacterial activity.
We now report on the synthesis and biological activities of a
series of non-, mono-, and bi-metallic compounds derived from
the structure of 1a. This study allows us to identify the indi-
vidual contribution of each organometallic component to the
antibacterial activity of this class of molecules.
Results and discussion
Synthesis and spectroscopic characterization
Compounds 9a–c were synthesized following a similar synthetic
route to that previously reported for 1a (Scheme 1).34 As a
representative example, the synthesis of 9c started with the CuI-
catalyzed [3 + 2] cycloaddition reaction35 of azidomethyl
benzene to the side chain of the alkyne-containing peptide
nucleic acid (PNA) building block 2.36 Compound 3 was isolated
in 82% yield. Formation of 3 was conrmed by the presence of
the characteristic singlet from the triazole ring at 5.30 ppm
(major isomer) and 5.39 ppm (minor isomer) in its 1H NMR
spectrum. The presence of two rotamers around the central
amide bond, usually denoted major (maj) and minor (min), is a
signature for this type of compounds.37 Treatment of 3 with
TFA, followed by amide coupling with p-iodo-aniline gave 5b in
52% yield. The Fmoc-group of 5b was then cleaved with 20%
piperidine in DMF. HATU-mediated peptide coupling of the
resulting residue with carboxylic acid 6a yielded compound 7c.
A signal at 199 ppm for the keto carbonyl group present in the
13C NMR spectrum of 7c conrmed the presence of the expected
compound. The last synthetic step involved the insertion of the
alkyne-substituted (dpa)Re(CO)3 complex (8)34 into the iodo-
substituted aromatic ring of 7c by Pd-catalyzed Sonogashira
coupling to give compound 9c. The 13C NMR spectrum of 9c
showed a signal at 195 ppm (rotamers present) corresponding
to the Re(CO)3 moiety present. Furthermore, a peak at m/z ¼
1071.9 for the [M-PF6]
+ species conrmed the formation of 9c.
Aer silica column chromatography, 9c was further puried by
semi-preparative RP-HPLC to remove trace amounts of impu-
rity. The counter anion of 9cwas therefore changed to CF3COO

and the compound was designated as 9c0. All new compounds
were characterized by NMR, ESI-mass spectrometry, and IR
Fig. 1 Structures of a few organometallic antimalarial and antibacterial
drug candidates (Ferroquine and Silvamist©) or drugs (Salvarsan).17
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spectroscopy. It is worth mentioning that all intermediates as
well as the nal compounds showed the presence of rotamers in
solution leading to a sometimes tedious assignment of 1H and
13C NMR signals. Compounds 5a, 6b, 7d were synthesized
following literature procedures.34,38 The purity of all compounds
used for biological activity test was checked by reverse phase
analytical HPLC and conrmed to be $95%.
Antimicrobial activity
The antimicrobial activities of all newly synthesized non-,
mono-, and bi-metallic derivatives were tested against gram-
positive Bacillus subtilis and Staphylococcus aureus strains
including an MRSA strain. The results are listed in Table 1. As
reported recently, the tri-metallic 1a inhibited growth of gram-
positive bacteria at MICs of 2 mg mL1.33 The analogous tri-
metallic compound 1b, in which the ferrocene moiety is
replaced by a ruthenocene unit, was found to be slightly less
active (MICs ¼ 4–32 mg mL1).33 Thus, oxidative stress by
ferrocene seems to enhance antibacterial potency but is not the
only component determining antibiotic activity.33 This is
consistent with the similar modes of action of both tri-metallic
compounds targeting the bacterial membrane.33 Among the
three bi-metallic derivatives, 7d lacks the [(dpa)Re(CO)3] moiety
but contains the ferrocenyl and CpMn(CO)3 moieties.
Compounds 9a and 9b have the [(dpa)Re(CO)3] moiety in
common. However, 9a contains a ferrocenyl moiety while 9b
contains the CpMn(CO)3. When tested for antibacterial activity,
7d was found to be inactive up to 512 mg mL1. However, both
derivatives 8a and 8b exhibited potent antibacterial activity with
MIC values in the range of 2–4 mg mL1. The mono-metallic
compounds lacking the [(dpa)Re(CO)3] moiety (5a, 7a, 7b) were
also inactive. In contrast, the mono-metallic derivative 9c0,
which contains the [(dpa)Re(CO)3] as the only organometallic
residue while both ferrocenyl and CpMn(CO)3 were replaced by
phenyl groups, was found to retain full antibacterial activity. It
inhibits the growth of MRSA at a concentration of 2 mg mL1
Scheme 1 Synthesis of mono- and bi-metallic, as well as metal-free compounds used in this study.
216 | Chem. Sci., 2015, 6, 214–224 This journal is © The Royal Society of Chemistry 2015
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Table 1 Antibacterial activity of the compounds against gram-positive bacterial strains. If required, the highest concentration tested was 512 mg
mL1. “ia” (inactive) designates no activity of the compound up to this highest concentration
Compound Structure
MIC
B. subtilis
S. aureus
DSM 20231
S. aureus
ATCC43300 (MRSA)
mg mL1 mM mg mL1 mM mg mL1 mM
1a (ref. 33) 2 1.4 2 1.4 2 1.4
1b (ref. 33) 32 21 4 2.7 6 4
7d ia ia ia
9a 4 3 2 1.5 2 1.5
9b 4 2.9 4 2.9 2 1.5
5a ia ia ia
7a ia ia ia
7b ia ia ia
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 214–224 | 217
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(Table 1). The activity is comparable to that of the parent
compound 1a and the bi-metallic derivatives 9a and 9b. These
results suggest that neither the ferrocene nor the CpMn(CO)3
moiety is essential, but the presence of the [(dpa)Re(CO)3]
moiety is indispensable for antibacterial activity. On the other
hand, the alkyne-substituted-[(dpa)Re(CO)3] complex 8 was
found to be inactive up to 512 mg mL1,33 demonstrating that
the organometallic moiety alone is not suﬃcient for antibiotic
activity but needs the pseudo-peptide backbone. The purely
organic intermediate compounds 5b and 7c were also inactive.
We then synthesized compound 10, the purely organic ligand of
the active mono-metallic derivative 9c0. Compound 10 was
found to have no antibacterial activity. This observation
emphasizes that the organometallic {Re(CO)3} fragment is
crucial for 9c0 to show antibacterial activity. Based on these
results, we suggest that neither ferrocene nor CpMn(CO)3 but
the {Re(CO)3} residue together with the pseudo-peptide back-
bone is essential for antibacterial activity. It is worth
mentioning that none of the active compounds 1a, 1b, 9a, 9b,
and 9c0 showed activity against gram-negative Pseudomonas
aeruginosa, Escherichia coli, or Acinetobacter baumannii. This
might be due to the presence of the outer membrane of gram-
negative bacteria, which hinders access of many compounds to
the cytoplasmic membrane where 1a exerts its activity.
Determination of solubility
Maximum solubility of the active derivatives was determined in
Belitzky minimal medium (BMM), a chemically dened bacte-
rial culture medium, and in Dulbecco's modied Eagle's
medium (DMEM), a standard growth medium for mammalian
cells (Table 2). Starting from 10 mg mL1 stock solutions of the
Table 1 (Contd. )
Compound Structure
MIC
B. subtilis
S. aureus
DSM 20231
S. aureus
ATCC43300 (MRSA)
mg mL1 mM mg mL1 mM mg mL1 mM
9c0 4 3.3 2 1.6 2 1.6
8 (ref. 33) ia ia ia
5b ia ia ia
7c ia ia ia
10 ia ia ia
Amoxicillin33 3 8.2 2 5.5 48 131
Noroxacin33 1 3.1 0.5 1.6 0.5 1.6
218 | Chem. Sci., 2015, 6, 214–224 This journal is © The Royal Society of Chemistry 2015
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compounds in DMSO, dilutions ranging from 1 mg mL1 to 1
mg mL1 were prepared in either BMM or DMEM. Aer 10 min
incubation at room temperature, samples were centrifuged and
checked for precipitated compounds visually and by light
microscopy (for micro-precipitates). The highest compound
concentration not leading to visible precipitates was dened as
maximum solubility. Compared to the tri-metallic 1a, the di-
and mono-metallic derivatives displayed two-fold higher solu-
bility in DMEM. In BMM, solubility of the di-metallic
compounds 9a and 9b was increased 4-fold. Solubility of the
mono-metallic compound 9c0 was even 12-fold higher
compared to that of 1a.
Determination of toxicity against mammalian cell lines
A good antibacterial compound should be selective towards
bacteria over mammalian cells. To obtain preliminary insight
into the toxicity, the active compounds (9a–b and 9c0) were
tested against two diﬀerent mammalian cancerous (HeLa and
HepG2) and a non-cancerous (MRC-5) cell lines. A metal-based
anticancer drug, cisplatin, was used as positive control (Table
3). As reported for 1a,33 cytotoxicity was found to be highly
dependent on the cell lines. For the tri-metallic 1a as well as the
bi-metallic 9a and 9b, IC50 values of 11–14 mg mL
1 (8–10 mM),
i.e. comparable to cisplatin were determined against HeLa cells.
In contrast, the same compounds showed moderate toxicity
against MRC-5 and were non-toxic to HepG2 cells up to 100 mM.
However, 1a, 9a and 9b are highly active against gram-positive
bacteria at a concentration of 2–4 mg mL1 (1.4–3 mM). Inter-
estingly, the mono-metallic derivative 9c0 exhibits only
moderate toxicity towards all mammalian cell lines studied in
this work with IC50 values of 31–63 mg mL
1 (26–52 mM), which
is 15–30 times higher than the MIC against MRSA (1.6 mM, 2
mg mL1). All in all, these results imply that the mono-metallic
compound 9c0 is not only highly selective for gram-positive over
gram-negative bacteria but also by at least one order of
magnitude less toxic to mammalian than to bacterial cells.
Inuence of 9a, 9b and 9c0 on the bacterial cell envelope
We showed that the bacterial membrane is the target structure
of compound 1a.33 Binding of 1a to the membrane leads to loss
of the membrane potential resulting in substantial energy
limitation. Depolarization is thereby thought to be caused by
interference with membrane-bound processes like respiration.
1a has also been shown to aﬀect membrane-bound steps of cell
wall biosynthesis, which is observed aer treatment with a
number of membrane-integrating compounds, e.g. some lanti-
biotics.12 In order to establish whether the active derivatives 9a,
9b, and 9c0 still have the same antibacterial mechanism, we
tested their inuence on membrane potential, membrane per-
meabilization, and cell wall integrity. The antimicrobial peptide
nisin, which binds to cell wall precursor lipid II and forms
membrane pores, was used as a positive control.39
Depolarization was indirectly monitored in B. subtilis using a
strain carrying a GFP fusion to the cell division protein MinD.
MinD depends on an intact membrane potential for correct
localization at the cell poles and the cell division plane (Fig. 2,
control in panel A).40 Upon depolarization, it delocalizes from
these spots. As shown before for 1a and conrmed herein for
the pore-forming compound nisin, all derivatives led to MinD
delocalization pointing to membrane depolarization (Fig. 2,
panels A). Subsequently, the BacLight assay was employed to
investigate if depolarization is accompanied by disruption of
the membrane structure. This staining method combines a
green-uorescent dye that crosses intact membranes and a red-
uorescent dye, which may only enter bacterial cells through
membrane pores or larger holes. In uorescence overlays, per-
meabilized cells appear orange. While the pore-forming nisin
led to red uorescencing cells, the compounds 9a, 9b, and 9c0
led to yellow to orange uorescence (Fig. 2, panel C). This
provides evidence for slight membrane permeabilization by 9a,
9b, and 9c0 rather than for organized pore formation. Per-
meabilization could be due to a detergent-like carpet mecha-
nism of action as was proposed for some antimicrobial
peptides.41 However, 1a was not shown to permeabilize the
bacterial membrane in the BacLight assay33 suggesting slight
Table 2 Maximum solubility (mg mL1) of active compounds in
bacterial and mammalian cell culture media. See text and expt section
for details of the procedure
Compounds In BMM (mg mL1) In DMEM (mg mL1)
1a 25 25
9a 100 50
9b 100 50
9c0 300 50
Table 3 Cytotoxicity of active compounds against mammalian cell lines (mg mL1 and mM). Values are given up to the limit of solubility (100 mM)
Compounds
IC50 values
HeLa HepG2 MRC-5
mg mL1 mM mg mL1 mM mg mL1 mM
1a 12.7  1 7.8  1.9 >145 >100 >145 >100
9a 13.5  2.6 10.2  2.0 >133 >100 30.2  4.1 22.8  3.1
9b 10.7  1.3 8.0  1.0 >134 >100 Not determined
9c0 31.2  0.9 26.3  0.8 62.5  11.5 52.7  9.7 43.7  5.9 36.9  5.0
Cisplatin 3.5  0.9 11.5  2.9 1.6  0.01 5.5  0.5 2.4  0.4 7.9  1.2
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diﬀerences in membrane interaction between the tri-metallic
compound and the di- or mono-metallic derivatives.
1a has been shown to aﬀect cell wall integrity, probably by
disturbing membrane-bound cell wall biosynthesis steps.33 The
eﬀects of the derivatives 9a, 9b, and 9c0 on cell wall integrity
were monitored by microscopic examination of the cell shape
aer xation with acetic acid and methanol. This treatment
reliably leads to membrane extrusions through cell wall holes,
which occur upon inhibition of membrane-bound cell wall
biosynthesis steps.42 Just like the positive control nisin, which
inhibits cell wall biosynthesis by binding to precursor lipid II,
all active compounds led to membrane extrusions (Fig. 2, panel
D). This demonstrates the same, probably indirect eﬀect on cell
wall biosynthesis by all derivatives. Taken together, 9a, 9b, and
9c0 still target the bacterial membrane and inuence cell wall
integrity but show more eﬃcient membrane permeabilization
than the tri-metallic 1a.
Conclusion
The urgent need for novel classes of antimicrobial compounds
is evidenced by rapidly growing bacterial resistance against the
conventional chemotherapeutic options. The discovery of novel
concepts is therefore highly desirable in order to identify new
structural classes of antibacterial compounds without a pre-
existing resistance history. We introduced (multi-)organome-
tallic-containing complexes as new class of antimicrobial agents
with a novel mode of action. Unlike our earlier belief that the
trimetallic nature was essential for activity of compound 1a, we
herein discovered the [(dpa)Re(CO)3] moiety as the crucial
component for potent activity against gram-positive bacteria,
including MRSA strains. Preliminary insight into the mode of
action of the bimetallic 9a, 9b, and the monometallic derivative
9c0 suggests that these compounds target the bacterial
membrane and have inuence on the cell wall integrity, simi-
larly to the trimetallic lead structure 1a. However, 9a, 9b and 9c0
showed even more eﬃcient membrane permeabilization ability
compared to 1a. Moreover, all active derivatives displayed
higher solubility in culture media than the trimetallic 1a, with
9c0 having the highest solubility. Finally, a determination of
toxicity against diﬀerent mammalian cell lines shows that the
monometallic derivative 9c0 is at least 15–30 times more toxic to
gram-positive bacteria than to the mammalian cell lines tested.
This diﬀerential activity is certainly encouraging enough for
Fig. 2 Inﬂuence of 9a, 9b, and 9c0 on B. subtilis membrane depolarization, membrane permeabilization, and cell wall integrity. (A) GFP-MinD
localization after antibiotic treatment. Disruption of the septal and polar localization of MinD is indicative of membrane depolarization. (B) Light
microscopy images of the cells shown above. (C) Antibiotic-treated cells stained with BacLight. The green dye is able to enter intact bacterial
cells. The red dye can only cross the bacterial membrane throughmembrane pores. In a ﬂuorescence overlay red or orange cells are indicative of
pore formation. (D) Antibiotic-stressed cells ﬁxed with acetic acid and methanol. Inhibition of the cell wall biosynthesis leads to holes in the cell
wall resulting in membrane excrescences after ﬁxation with acetic acid/methanol.
220 | Chem. Sci., 2015, 6, 214–224 This journal is © The Royal Society of Chemistry 2015
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
O
ct
ob
er
 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
2/
12
/2
01
4 
15
:1
1:
05
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
further development. So far, Re(I) tricarbonyl compounds are
well-known for their luminescent properties and anticancer
therapeutic potential.13,43–50 To the best of our knowledge, this is
the rst study reporting that a {ReI(CO)3} core with an appro-
priate organic ligand is a promising new lead structure for the
development of antibacterial compounds.
Experimental section
Materials
All chemicals were of reagent grade quality or better, obtained
from commercial suppliers, and used without further purica-
tion. Solvents were used as received or dried over molecular
sieves. All preparations were carried out using standard Schlenk
techniques. Reactions involving CpMn(CO)3-containing
compounds were carried out in the dark. N,N-bis(pyridine-2-
ylmethyl)prop-2-yn-1-amine, compound 2, 5a, 6b, 7d, and 8
were synthesized following the literature procedure.34,36,38,51 The
analytical data matched those previously reported. For all newly
synthesized compounds, except 9c, detailed synthesis proce-
dures and full analytical data are presented in the ESI.†
Instrumentation and methods
1H and 13C NMR spectra were recorded in deuterated solvents
on Bruker DRX 200, 250, 400, or 600 spectrometers at 30 C.
Chemical shis d are reported in ppm (parts per million),
coupling constants J are given as absolute values in Hz. The
residual solvent peaks have been used as an internal reference.
Abbreviations for the peak multiplicities are as follows: s
(singlet), d (doublet), dd (doublet of doublets), t (triplet), q
(quartet), m (multiplet), and br (broad). Infrared spectra were
recorded on an ATR unit using a Bruker Tensor 27 FTIR spec-
trophotometer at 4 cm1 resolution. Signal intensity is abbre-
viated br (broad), s (strong), m (medium), and w (weak). ESI
mass spectra were recorded on a Bruker Esquire 6000. Analyt-
ical HPLC was performed using a Nucleosil 100-5 C18 column
(250  3 mm) on a Hitachi chromaster HPLC system at 25 C.
The ow rate was 0.5 mL min1 and UV-absorption was
measured at 250 nm. The runs were performed with a linear
gradient of A acetonitrile (Sigma-Aldrich HPLC-grade) and B
(distilled water containing 0.1% v/v TFA): t¼ 0–3 min, 5% A; t¼
17–22 min, 100% A; t¼ 22–25 min, 5% A. Preparative HPLC was
performed using a Nucleosil 100-7 C18 column (250  21 mm)
on a Varian Prostar HPLC system at 25 C. The ow rate was 15
mL min1 and UV-absorption was measured at 250 nm. The
runs were performed with a linear gradient of A acetonitrile
(Sigma-Aldrich HPLC-grade) and B (distilled water containing
0.1% v/v TFA): t ¼ 0–3 min, 10% A; t ¼ 3–6 min, 50% A; t ¼ 6–23
min, 100% A; t ¼ 23–27 min, 100% A, t ¼ 30 min, 100% A.
Compound 9c
A solution of 7c (371mg, 0.53mmol) and 8 (350mg, 0.53mmol) in
12 mL DMF/NEt3 mixture (2/1, v/v) was degassed by two ‘freeze–
pump–thaw’ cycles. Then CuBr (9.86 mg, 0.07 mmol) and cis-
dichlorobis (triphenylphosphine) palladium(II) (7.7 mg, 0.01
mmol) were added under nitrogen atmosphere and the mixture
was degassed again by one ‘freeze–pump–thaw’ cycle. The wine
color solution thus obtained was allowed to stir 20 h at room
temperature. The solvent was removed and the residue was
diluted with 100 mL of CH2Cl2, washed with distilled water (4 
60 mL) and brine (2  60 mL). The CH2Cl2 layer was dried over
Na2SO4, ltered and concentrated. The solid was then loaded on a
silica column and eluted immediately with CH2Cl2 : MeOH 5 : 1 >
3 : 1. The combined fractions was evaporated and redissolved in
CH2Cl2 and ltered. Filtrate was dried to give 9c as light brown
solid (yield: 256 mg, 39%). For biological applications purpose 9c
was further puried by RP-HPLC to remove a trace of impurity
present aer purication by silica column chromatography. Thus
the counter anion PF6
 of 9c changed to CF3COO
 and the
compound was designated as 9c0. Data for 9c: Rf¼ 0.51 (silica gel,
CH2Cl2 : MeOH 4 : 1). tR (RP-HPLC) ¼ 16.8 min. 1H NMR (250
MHz, CD2Cl2): d (ppm) 2.54 (m, 2H, Ph–CO–CH2–CH2), 2.75 (min)
and 2.82 (maj) (rotamers, m, 2H, CH2–CH2–triazole ring), 3.03 (m,
2H, CH2–CH2–triazole ring), 3.27 (m, 2H, PhCO–CH2–CH2), 3.34–
3.56 (m, 4H, NH–CH2–CH2–N and NH–CH2–CH2–N), 4.15 (maj)
and 4.32 (min) (rotamers, s, 2H, N–CH2–CO), 4.68 (min) and 4.71
(maj) (rotamers, s, 2H, N–CH2–C^C), 4.87–5.18 (rotamers, m, 4H,
2  N–CH2–Py), 5.42 (maj) and 5.45, 5.20 (min) (rotamers, s, 2H,
triazole–CH2–Ph), 6.52, 6.78 (min) and 6.99 (maj) (rotamers, 1H,
NHCO), 7.19–7.50 (m, 13H, 1  triazole ring H and 12  aromatic
H), 7.56–7.69 (m, 4H, aromatic H), 7.82–7.95 (m, 4H, aromatic H),
8.76 (m, 2H, aromatic H), 9.43 (maj) and 9.50, 9.60, 10.13 (min)
(rotamers, NHCO). 13C NMR (62.9 MHz, CD2Cl2): d (ppm) 20.9
(min) and 21.1 (maj) (rotamers, CH2–CH2–triazole ring), 29.6
(maj) and 39.9 (min) (rotamers, PhCO–CH2–CH2), 31.6 (maj) and
31.9 (min) (rotamers, CH2–CH2–triazole ring), 33.6 (maj) and 33.9
(min) (rotamers, PhCO–CH2–CH2), 37.9 (maj) and 38.3 (min)
(rotamers, NH–CH2–CH2–N), 49.1 (NH–CH2–CH2–N), 51.8 (N–
CH2–CO), 52.1 (Ph–CH2–triazole ring, overlaps with solvent
residual signal), 59.1 (maj) and 59.2 (min) (rotamers, N–CH2–
C^C), 68.1, 68.3 (maj) and 72.2, 72.4 (min) (rotamers, 2  N–
CH2–Py), 80.8 (C^C–CH2–N), 90.3 (N–CH2–C^C), 116.1 (maj)
and 116.3 (min) (rotamers, aromatic C), 119.5, 120.1 (min) and
119.7 (maj) (rotamers, aromatic C), 121.6 (min) and 121.9 (maj)
(rotamers, CH triazole ring), 123.9 (aromatic C), 124.2 (aromatic C),
125.4, 125.6 (min) and 125.8, 125.9 (maj) (rotamers, 2  aromatic
C), 127.8 (min) and 127.9 (maj) (rotamers, aromatic C), 128.4 (min)
and 128.5 (maj) (rotamers, aromatic C), 128.9 (aromatic C), 132.7
(aromatic C), 133.1 (aromatic C), 135.2 (aromatic C), 136.6 (aromatic
C), 139.3 (min) and 139.6 (maj) (rotamers, aromatic C), 140.5
(aromatic C), 146.7 (maj) and 147.1 (min) (rotamers, C triazole
ring), 151.4 (min) and 151.6 (maj) (rotamers, aromatic carbon),
159.3 (min) and 159.6 (maj) (rotamers, aromatic C), 167.1, 167.9,
168.1 (min) and 168.4 (maj) (rotamers, CONH), 172.4 (CONH),
173.4 (maj) and 173.6 (min) (rotamers, CH2CON), 194.9 (min) and
195.3 (maj) (rotamers, Re–CO), 198.8 (min) and 199.2 (maj)
(rotamers, Ph–CO). IR bands (n): 2032s, 1913s, 1670m (br) cm1.
ESI-MS (pos. detection mode): m/z (%): 1071.98 (100) [M-PF6]
+.
Minimal inhibitory concentration (MIC)
The minimal inhibitory concentrations (MIC) were tested
against Escherichia coli DSM 30083, Acinetobacter baumannii
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 214–224 | 221
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DSM 30007, Pseudomonas aeruginosa DSM 50071, Bacillus sub-
tilis DSM 402, Staphylococcus aureus DSM 20231, and Staphylo-
coccus aereus ATCC 43300 (MRSA) in a microtiter plate assay
according to CLSI guidelines.52 E. coli, A. baumannii, S. aureus,
and B. subtilis were grown in Mueller Hinton broth, P. aerugi-
nosa in cation adjusted Mueller Hinton II. Compounds were
dissolved in DMSO to give 10 mg mL1 stock solutions. Serial
dilution in culture media was carried out automatically with the
Tecan Freedom Evo 75 liquid handling workstation (Tecan,
Ma¨nnedorf, Switzerland) from 512 to 0.5 mg mL1. Compound
dilutions were inoculated with 105 bacteria per mL taken from
late exponential cultures grown in the same media in a total
volume of 200 mL per well. Cells were incubated for 16 hours at
37 C. The lowest compound concentration inhibiting visible
bacterial growth is reported as MIC.
Mammalian cell culture and cytotoxicity test
Cytotoxicity studies were performed on three diﬀerent cell lines
by a uorometric cell viability assay using Resazurin (Promocell
GmbH). Human cervical carcinoma cells (HeLa) were cultured
in DMEM (Gibco) supplemented with 5% fetal calf serum (FCS,
Gibco), 100 U mL1 penicillin, 100 mg mL1 streptomycin at
37 C and 5% CO2. The normal human lung broblast MRC-5
cell line was maintained in F-10 medium (Gibco) supplemented
with 10% FCS (Gibco), penicillin (100 U mL1), and strepto-
mycin (100 mg mL1). The human hepatomacarcinoma (HepG2)
cells were cultured in DMEM (Gibco) supplemented with 10%
fetal calf serum (FCS, Gibco), 100 U mL1 penicillin, 100
mg mL1 streptomycin at 37 C and 5% CO2.
One day before treatment, cells were seeded in triplicate in
96-well plates at a density of 4  103 cells per well for HeLa and
HepG2, and 7  103 for MRC-5 in 100 mL growth medium.
Compounds were dissolved in DMSO to give 10 mg mL1 stock
solutions, serial dilutions were prepared using respective cell
culture media. Upon treating cells with increasing concentra-
tions of respective compounds for 48 h, the medium was
removed, and 100 mL fresh culture medium containing Resa-
zurin (0.2 mg mL1 nal concentration) was added. Aer 4 h of
incubation at 37 C, uorescence of the highly red uorescent
product resorun was quantied at 590 nm emission with
540 nm excitation wavelength in a SpectraMax M5 microplate
Reader.
GFP-MinD delocalization assay
B. subtilis 1981 GFP-MinD40 was grown in Belitzky Minimal
Medium (BMM)53 until early logarithmic phase. The main
culture was subdivided and aliquots were treated with 8
mg mL1 (2MIC) 9a, 9b, and 9c0, respectively, or le untreated
as control. Nisin was used as positive control at a concentration
of 0.75 mg mL1. Aer 15 minutes of antibiotic stress, cells were
microscopically examined in uorescent mode as described
previously.54
BacLight™ membrane disruption assay
BacLight staining (LIVE/DEAD BacLight Bacterial Viability Kit,
Invitrogen, Carlsbad, CA, USA) was performed following the
manufacturer's instructions. B. subtilis 168 (ref. 55) was grown
and stressed with antibiotics as described above. Aer 15
minutes of antibiotic exposure, cells were stained with a 1 : 1
mixture of SYTO 9 and propidium iodide (1 mL per mL cells) for
15 minutes, washed twice in 100 mM Tris/1 mM EDTA, pH 7.5,
resuspended in the same buﬀer and subjected to uorescence
microscopy.
Cell wall integrity assay
B. subtilis 168 was grown and stressed with antibiotics as
described above. Aer 15 minutes of antibiotic treatment, 200
mL of culture were withdrawn and immediately xed in 1 mL of
a 1 : 3mixture of acetic acid andmethanol. 5 mL of xed bacteria
were immobilized in agarose and subjected to light microscopy
as described previously.54
Solubility in media
All compounds were dissolved as 10 mgmL1 stock solutions in
DMSO, and rst dilutions were prepared with sterile double-
distilled water. Concentration series of the compounds ranging
from 1 mg mL1 to 1 mg mL1 were prepared in either BMM or
DMEM (diluted from stock solutions as described above). Aer
10 min incubation at room temperature, samples were centri-
fuged at 16 100 g for 10 min (room temperature). Precipitated
compounds were visible as pellets. Samples without visible
precipitation were mixed again and checked for micro-
precipitates by light microscopy (Olympus BX51 equipped with
a U-UCD8 condenser and a UPlanSApo 100XO objective). The
highest compound concentration not leading to visible precip-
itates was dened as maximum solubility. Experiments were
performed independently as duplicates.
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